Skip to main content
2023 IKCS: Europe Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers)

Attending Physician
Vall d'Hebron University Hospital
Barcelona, Catalonia, Spain

Dr. Cristina Suárez received her M.D in Medicine and Surgery at the Autonomous University of Barcelona. She gets a Specialist Training, Medical Oncology at the Faculty of Medicine, Autonomous University of Barcelona. “Hospital del Mar – Parc de la Salut” of Barcelona. In 2008, she joined the Oncology Department of Vall d’Hebron University Hospital as Physician (attending staff), of the Genitourinary, Central Nervous System, Sarcoma and Tumors of Unknown Origin Program. In 2018 obtained “Cum Laude” qualification when she completes her studies of doctorate with the doctoral thesis: “Prognostic value of genetic alterations in the mTOR pathway of patients with metastatic renal cell carcinoma treated with mTOR inhibitors”.

Dr Suarez is a medical oncologist and clinical investigator at the Genitourinary, Central Nervous System (CNS) tumors, Sarcoma and Cancer of Unknown Primary Site Group, with special focus on kidney and bladder cancer. The group is focused on the design and development of clinical trials and translational studies that allow treatment optimization and the development of new and disruptive treatment options for those patients. Dr Suarez has been principal investigator and co-investigator in more than 100 clinical trials throughout her career, mainly in the genitourinary, brain and sarcoma tumor area, as well as phase I clinical trials.
Research highlights include clinical development of immunotherapy in her area of knowledge. Some relevant studies in which Dr. Suarez has had a relevant role include CHECKMATE-9ER, which demonstrated first line efficacy of Nivolumab-Cabozantinib in clear cell renal cell carcinoma (RCC), KEYNOTE-427, which showed the efficacy of pembrolizumab in non-clear cell RCC. Dr. Suarez has had a critical role in all the mentioned studies.
One of her main areas of interest is biomarkers, she is involved in several biomarker studies and has been a co-author of some of them such as the IMMOTION 151.
Another relevant highlight includes the CALYPSO trial, which focuses on molecular alteration selection in patients leads to a better outcome in renal papillary tumors. She has also participated in several investigator-initiated trials and is involved in several steering committees of relevant trials.

Disclosure information not submitted.

Presentation(s):

Email Cristina